Targeting STAT3 and MEK/ERK/BCL2 activity by specific inhibitors resulted in significant MM cell death and growth inhibition and their combinations had a synergistic cytotoxic effect on myeloma cells. This evidence concerns the gene STAT3 and plasma cell myeloma.